Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, “Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.” While market reaction was muted, management acknowledged the impact of higher operating expenses, including acquisition-related charges, on overall profitability.
Is now the time to buy MRK? Find out in our full research report (it’s free for active Edge members).
Merck (MRK) Q2 CY2026 Highlights:
- Revenue: $16.61 billion vs analyst estimates of $16.27 billion (5.1% year-on-year growth, 2.1% beat)
- Adjusted EPS: -$0.13 vs analyst estimates of -$0.26 (49.5% beat)
- The company slightly lifted its revenue guidance for the full year to $66.8 billion at the midpoint from $66.4 billion
- Management lowered its full-year Adjusted EPS guidance to $2.71 at the midpoint, a 46.9% decrease
- Operating Margin: -3.5%, down from 31.6% in the same quarter last year
- Constant Currency Revenue rose 4% year on year (-2% in the same quarter last year)
- Market Capitalization: $323 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Merck’s Q2 Earnings Call
- Akash Tewari (Jefferies) asked about the potential for a broad sac-TMT plus pembrolizumab trial in first-line lung cancer. Dr. Dean Li, President of Research Labs, confirmed plans for such trials and discussed strategies for differentiating in crowded indications.
- Umer Raffat (Evercore) inquired about how TL1A activity compares to established TNF inhibitors in new indications. Dr. Li detailed Merck’s confidence in TL1A, particularly in gastrointestinal and dermatological diseases, citing biomarker data and positive trial results.
- Geoffrey Meacham (Citi) questioned the expected pace of LIPFENDRA’s commercial adoption and the role of outcomes trials. CEO Robert Davis noted high initial interest but set expectations for a gradual ramp as payer access develops.
- Michael Yee (UBS) probed the ulcerative colitis program and setbacks in fibrosis studies. Dr. Li explained the challenges of the SSc-ILD study and maintained confidence in the broader immunofibrosis strategy.
- Jason Gerberry (Bank of America) asked about market expansion potential for oral PCSK9s in primary care. Davis emphasized Merck's focus on expanding the market beyond injectable PCSK9 share, targeting millions not at LDL goals.
Catalysts in Upcoming Quarters
In future quarters, StockStory analysts will monitor (1) continued adoption and access for LIPFENDRA and IDVYNSO, (2) pivotal clinical trial readouts for sac-TMT, tulisokibart, and key HIV assets, and (3) the pace of margin recovery as integration costs and R&D investments are absorbed. Ongoing product launches and regulatory milestones will be important markers of execution.
Merck currently trades at $129.75, up from $127.77 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.